Covid-19/

Francesca Biagioni

Education

  • 2010-present
    Translational Oncogenomic Unit - Regina Elena Cancer Institute - Rome - ITALY
    Post-doctoral fellow - Principal Investigator: Dr.Giovanni Blandino
  • 2006-2010
    Translational Oncogenomic Unit - Regina Elena Cancer Institute – Rome - ITALY
    PhD in Immunological Sciences, Molecular Medicine - La Sapienza University - Rome
    Thesis: The advent of microRNAs in the molecular taxonomy of breast cancer
    Supervisor: Dr Giovanni Blandino
  • 2003-2005
    University of Trieste - Faculty of Medicine – Trieste - ITALY
    Master Degree (Laurea specialistica) in Medical Biotechnology (110/110 cum laude)
    Thesis: Study of voltage dependent calcium channel involved in Spinocerebellar Ataxia type 6 through yeast two hybrid technique
    Supervisor: Dr.Stefano Gustincich and Dr.Francesca Persichetti (SISSA - Trieste)
  • 2000-2003
    University of Trieste - Faculty of Medicine – Trieste - ITALY
    Bachelor’s degree (Laurea triennale) in Biotechnology  (109/110)
    Thesis: Identification of early marker of oxidative stress in eukaryotic cells through differential proteomic approach
    Supervisor: Dr Gianluca Tell

Pubblications

  • “miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumors”
    Biagioni F*, Bossel Ben-Moshe N*, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto B, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E and Blandino G
    *Authors contribute equally
    EMBO Mol Med. 2012 Nov;4(11):1214-29
  • “miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer”
    Sacconi A*, Biagioni F*, Canu V*, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro MG, Pescarmona E, Garofalo A and Blandino G
    *Authors contribute equally
    Cell Death and Disease in press
  • “Metformin elicits anticancer effects through the sequential modulation of DICER, microRNA33 and c-MYC”
    Blandino G*, Valerio M*, Cioce M*, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Citro G, Muti P and Strano S
    *Authors contribute equally
    Nat Commun. 2012 May 29;3:865.
  • “The mitogen activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms”
    Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubreys JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, Cognetti F, De Maria R, Del Bufalo D and Milella M
    J Mol Med (Berl). 2012 Jan 4
  • “microRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function”
    Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S and Blandino G
    Cell Death and Differentiation, 2011 Dec 23. doi: 10.1038/cdd.2011.190
  • “Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feed back loop”
    Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, and Di Agostino S
    Cell Cycle. 2011 Dec 15;10(24)
  • “EGF Downregulates microRNAs that Normally Restrain Oncogenic Transcription Factors”
    Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G,Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Børresen-Dale AL, Pilpel Y, Yakhini H, Segal E and  Yarden Y
    Science Signalling, Jun 1; 3 (124): ra43
  • “Oncogenomic approaches in exploring gain of function of mutant p53”
    Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G and Blandino G.
    Current genomics, vol 9, Number 3, May 2008, pp. 200-207(8)